Coherex Medical has closed a $16.5 million Series B preferred stock financing. After the close of this investment, Coherex has now raised nearly $28 million in equity financing from outside funding sources since inception.
The Salt Lake City-based company said vSpring Capital and Oxford Bioscience Partners co-led investors on this financing, and both venture capital firms participated in its prior Series A preferred stock financing. Also, joining vSpring and Oxford in the Series B financing were Tullis Health Investors, a venture capital firm focused on the healthcare industry.
In June, the Coherex FlatStent EF device received CE Mark clearance for closing patent foramen ovale, a heart defect found in approximately 20 percent of people worldwide.